Posts by Peter W. PENG

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded successfully in Orlando, USA. As the “grand finale” of the hematology field each year, this meeting showcased a series of cutting-edge breakthroughs in lymphoma research, providing new directions for optimizing clinical practice.

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…

At the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. Lucy Fox from the Peter MacCallum Cancer Centre (Australia) presented the highly anticipated results of the IBMDX study. This landmark trial evaluated the clinical utility and economic impact of "Upfront Whole Genome Sequencing (WGS)" in patients with suspected Inherited Bone Marrow Failure Syndromes (IBMFS). The findings suggest a paradigm shift is underway: WGS not only achieves a diagnostic yield of 37%—surpassing traditional panels and exome sequencing—but also uncovers complex genomic mechanisms previously invisible to standard testing.

From December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, bringing together leading experts worldwide to present the latest breakthroughs in…

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025, bringing together the latest global advances in hematologic research and clinical practice. At this year’s meeting, four studies led by Prof. Yajing Zhang from Beijing Gobroad Boren Hospital were accepted, including one oral presentation.

The 2025 Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9. As one of the world’s premier events in hematology, the…